Professor Brown and Ms Jacquie Taylor in the Illumina Genotyping Facility Scientists have isolated at least 25 genes that cause seven of the most common hereditary diseases including diabetes and arthritis in the world’s largest genetic study.
Researchers from the Division of Health Promotion & Sports Medicine at Oregon Health & Science University have found steroid use among teen girls is not limited to athletes and often goes hand in hand with other unhealthy choices, including smoking and taking diet pills.
“Have I been here before”? In today’s fast-moving world of look-alike hotel rooms and comparable corridors, it can take a bit of thinking to answer this simple question.
Researchers at the University of Pennsylvania School of Medicine have discovered a potential new target for treating type 2 diabetes, according to a new study that appeared online this week in Nature. The target is a protein, along with its molecular partner, that regulates fat metabolism.
Early life sun exposure, from birth to 20 years old, may specifically increase the risk of melanomas with BRAF gene mutations. Skin cancers often contain different gene mutations, butjust how these mutations contribute to the cause of melanomas has been amystery.
Researchers at USC and Caltech slow aging dramatically in fruit flies with a new technique that shows general promise in pharmaceutical development.
While the symptoms of bipolar disorder can be disabling on their own, most patients with the condition also are afflicted with a variety of other psychiatric, substance use and physical disorders.
Endocannabinoids seem to play an important role in regulating inflammation processes. Scientists from the University of Bonn have discovered this in experiments on mice.
A drug described by some people as a “genius pill”for enhancing cognitive function provided relief to a small group of Rochester breast cancer survivors who were coping with a side effect known as “chemo-brain,”according to a University of Rochester Medical Center study.
GlaxoSmithKline plc [LSE and NYSE: GSK] announced long-term efficacy data from a Phase II trial of a single one-week course of frontline treatment with the BEXXAR? Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in 76 patients with newly diagnosed advanced follicular non-Hodgkin?s lymphoma (NHL).